Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Abstract

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.